Evogene (EVGN) said Monday it has struck a deal for ICL to acquire the majority of activity of its subsidiary, Lavie Bio, which focuses on improving agriculture productivity.
The company said ICL will also acquire its MicroBoost AI for AG platform as part of the agreement.
Evogene said key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, microbial bank and data assets. It expects to close the deal in Q2.
"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said Chief Executive Ofer Haviv.
The shares shares were up about 20% in recent trading.
Price: 1.17, Change: +0.20, Percent Change: +20.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。